Details for Patent: 11,154,593
Which drugs does patent 11,154,593 protect, and when does it expire?
Patent 11,154,593 protects YUVIWEL and is included in one NDA.
This patent has fifteen patent family members in seven countries.
Summary for Patent: 11,154,593
| Title: | CNP prodrugs with large carrier moieties |
| Abstract: | The present invention relates to a CNP prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety -D; and a carrier moiety —Z that is conjugated through a moiety -L2- to a reversible prodrug linker moiety -L1-, which reversible prodrug linker moiety -L1- is covalently and reversibly conjugated to -D; wherein -L2- is a chemical bond or a spacer; and —Z is a polymer having a molecular weight of at least 10 kDa. It further relates to pharmaceutical compositions comprising the CNP prodrug or a pharmaceutically acceptable salt thereof, their use as a medicament and to methods of treatment. |
| Inventor(s): | Harald Rau, Ulrich Hersel, Felix Cleemann, Caroline Elisabeth Rasmussen |
| Assignee: | Ascendis Pharma Endocrinology Division AS |
| Application Number: | US17/184,561 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 11,154,593
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ascendis | YUVIWEL | navepegritide | POWDER;SUBCUTANEOUS | 219164-001 | Feb 27, 2026 | RX | Yes | Yes | 11,154,593 | ⤷ Start Trial | Y | Y | INCREASE OF LINEAR GROWTH IN PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH ACHONDROPLASIA WITH OPEN EPIPHYSES | ⤷ Start Trial | ||
| Ascendis | YUVIWEL | navepegritide | POWDER;SUBCUTANEOUS | 219164-002 | Feb 27, 2026 | RX | Yes | Yes | 11,154,593 | ⤷ Start Trial | Y | Y | INCREASE OF LINEAR GROWTH IN PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH ACHONDROPLASIA WITH OPEN EPIPHYSES | ⤷ Start Trial | ||
| Ascendis | YUVIWEL | navepegritide | POWDER;SUBCUTANEOUS | 219164-003 | Feb 27, 2026 | RX | Yes | Yes | 11,154,593 | ⤷ Start Trial | Y | Y | INCREASE OF LINEAR GROWTH IN PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH ACHONDROPLASIA WITH OPEN EPIPHYSES | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,154,593
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2017205268 | ⤷ Start Trial | |||
| Australia | 2022201416 | ⤷ Start Trial | |||
| Canada | 3007976 | ⤷ Start Trial | |||
| European Patent Office | 3400020 | ⤷ Start Trial | |||
| Japan | 2019507724 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
